Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.

Also called NCT04595370

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 153 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04595370
  • EudraCT 2020-003126-23
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Bulgaria, Canada, Czechia, Denmark, Germany, Hungary, India, Italy, Japan, Lithuania, Poland, Russia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04595370. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-26 (actual); primary completion 2023-09-22 (actual). Results posted on 2024-11-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
Acronym
MIRACLE
Condition
Heart Failure
Intervention (Drug)
AZD9977
Intervention (Drug)
Dapagliflozin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04595370
Content hash
78899c04591de25f1b3624cbf62b5ab87526ed54f23ad3c9f1eb918646093c8a